Is high-dose Leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial

Seung Hwan Lee, Hyun Moo Lee, Sae Woong Kim, Eun Sik Lee, Sung Joon Hong, Choung Soo Kim, Taek Won Kang, Byungha Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Leuprorelin is a well known luteinizing hormone releasing hormone agonist. However, there are insufficient data on the efficacy and safety of high dose leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at three-month intervals in patients with prostate cancer. Materials and Methods: In an open, prospective clinical trial enrolling 47 patients, we aimed to assess the efficacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologically confirmed prostate cancer. The primary objective of this study was to evaluate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining castration levels of testosterone over a 6-month follow-up period and to determine its safety profile. Results: All 42 patients achieved serum testosterone levels within the castration range by 4 weeks. A breakthrough response was observed in one of 36 patients by 8 weeks. However, this patient was medically castrated by 12 weeks. There were no significant prostate-specific antigen (PSA) or testosterone changes according to clinical stage or body mass index. Twenty adverse events (AEs) in 15 of 42 patients (35.7%) were observed during this study. The most common AEs were hot flushes (n=4, 20.0%) with mild intensity, pain (n=2, 10.0%), and infection (n=2, 10.0%). No patient withdrew from the study due to AEs. Conclusion: Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian patients with prostate cancer, even though sexual function decreased.

Original languageEnglish
Pages (from-to)310-315
Number of pages6
JournalYonsei Medical Journal
Volume55
Issue number2
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Leuprolide
Prostatic Neoplasms
Acetates
Clinical Trials
Safety
Testosterone
Castration
Prostate-Specific Antigen
Gonadotropin-Releasing Hormone
Body Mass Index

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Seung Hwan ; Lee, Hyun Moo ; Kim, Sae Woong ; Lee, Eun Sik ; Hong, Sung Joon ; Kim, Choung Soo ; Kang, Taek Won ; Chung, Byungha. / Is high-dose Leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial. In: Yonsei Medical Journal. 2014 ; Vol. 55, No. 2. pp. 310-315.
@article{a13f469d4ee84baa80ebbd60a8e487cc,
title = "Is high-dose Leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial",
abstract = "Purpose: Leuprorelin is a well known luteinizing hormone releasing hormone agonist. However, there are insufficient data on the efficacy and safety of high dose leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at three-month intervals in patients with prostate cancer. Materials and Methods: In an open, prospective clinical trial enrolling 47 patients, we aimed to assess the efficacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologically confirmed prostate cancer. The primary objective of this study was to evaluate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining castration levels of testosterone over a 6-month follow-up period and to determine its safety profile. Results: All 42 patients achieved serum testosterone levels within the castration range by 4 weeks. A breakthrough response was observed in one of 36 patients by 8 weeks. However, this patient was medically castrated by 12 weeks. There were no significant prostate-specific antigen (PSA) or testosterone changes according to clinical stage or body mass index. Twenty adverse events (AEs) in 15 of 42 patients (35.7{\%}) were observed during this study. The most common AEs were hot flushes (n=4, 20.0{\%}) with mild intensity, pain (n=2, 10.0{\%}), and infection (n=2, 10.0{\%}). No patient withdrew from the study due to AEs. Conclusion: Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian patients with prostate cancer, even though sexual function decreased.",
author = "Lee, {Seung Hwan} and Lee, {Hyun Moo} and Kim, {Sae Woong} and Lee, {Eun Sik} and Hong, {Sung Joon} and Kim, {Choung Soo} and Kang, {Taek Won} and Byungha Chung",
year = "2014",
month = "3",
day = "1",
doi = "10.3349/ymj.2014.55.2.310",
language = "English",
volume = "55",
pages = "310--315",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Is high-dose Leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial. / Lee, Seung Hwan; Lee, Hyun Moo; Kim, Sae Woong; Lee, Eun Sik; Hong, Sung Joon; Kim, Choung Soo; Kang, Taek Won; Chung, Byungha.

In: Yonsei Medical Journal, Vol. 55, No. 2, 01.03.2014, p. 310-315.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is high-dose Leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial

AU - Lee, Seung Hwan

AU - Lee, Hyun Moo

AU - Kim, Sae Woong

AU - Lee, Eun Sik

AU - Hong, Sung Joon

AU - Kim, Choung Soo

AU - Kang, Taek Won

AU - Chung, Byungha

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose: Leuprorelin is a well known luteinizing hormone releasing hormone agonist. However, there are insufficient data on the efficacy and safety of high dose leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at three-month intervals in patients with prostate cancer. Materials and Methods: In an open, prospective clinical trial enrolling 47 patients, we aimed to assess the efficacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologically confirmed prostate cancer. The primary objective of this study was to evaluate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining castration levels of testosterone over a 6-month follow-up period and to determine its safety profile. Results: All 42 patients achieved serum testosterone levels within the castration range by 4 weeks. A breakthrough response was observed in one of 36 patients by 8 weeks. However, this patient was medically castrated by 12 weeks. There were no significant prostate-specific antigen (PSA) or testosterone changes according to clinical stage or body mass index. Twenty adverse events (AEs) in 15 of 42 patients (35.7%) were observed during this study. The most common AEs were hot flushes (n=4, 20.0%) with mild intensity, pain (n=2, 10.0%), and infection (n=2, 10.0%). No patient withdrew from the study due to AEs. Conclusion: Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian patients with prostate cancer, even though sexual function decreased.

AB - Purpose: Leuprorelin is a well known luteinizing hormone releasing hormone agonist. However, there are insufficient data on the efficacy and safety of high dose leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at three-month intervals in patients with prostate cancer. Materials and Methods: In an open, prospective clinical trial enrolling 47 patients, we aimed to assess the efficacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologically confirmed prostate cancer. The primary objective of this study was to evaluate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining castration levels of testosterone over a 6-month follow-up period and to determine its safety profile. Results: All 42 patients achieved serum testosterone levels within the castration range by 4 weeks. A breakthrough response was observed in one of 36 patients by 8 weeks. However, this patient was medically castrated by 12 weeks. There were no significant prostate-specific antigen (PSA) or testosterone changes according to clinical stage or body mass index. Twenty adverse events (AEs) in 15 of 42 patients (35.7%) were observed during this study. The most common AEs were hot flushes (n=4, 20.0%) with mild intensity, pain (n=2, 10.0%), and infection (n=2, 10.0%). No patient withdrew from the study due to AEs. Conclusion: Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian patients with prostate cancer, even though sexual function decreased.

UR - http://www.scopus.com/inward/record.url?scp=84894225886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894225886&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.2.310

DO - 10.3349/ymj.2014.55.2.310

M3 - Article

VL - 55

SP - 310

EP - 315

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -